The patent, titled “Methods for Treating Eye Conditions,” broadly states the technology can be used to treat eye conditions such as glaucoma, cataracts and presbyopia.
BIOLASE has a presence in the ophthalmology market with its wholly owned subsidiary OCCULASE.
More Articles on Ophthalmology:
ARVO Names Dr. Justine Smith President, Dr. William Mieler President-Elect
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
Valeant Acquires Bausch + Lomb for $8.7B
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
